Genmab — Februar 2022
-
God morgen.
-
Tirsdagens aviser med Danske Bank, Novo Nordisk og Jyske Bank
https://www.proinvestor.com/investornyt/774087/tirsdagens-aviser-med-danske-bank-novo-nordisk-og-jyske-bank -
Asien: Positiv udvikling på de få åbne børser - NY
https://www.proinvestor.com/investornyt/774096/asien-positiv-udvikling-pa-de-fa-abne-borser-ny -
Upifitamab Rilsodotin Has Potential to Address Unmet Need in Recurrent Ovarian Cancer https://www.onclive.com/view/upifitamab-rilsodotin-has-potential-to-address-unmet-need-in-recurrent-ovarian-cancer
-
"The best opportunity in cervical cancer is tisotumab vedotin, where the target, which is tissue factor, is ubiquitous in cervical cancer, so there is no biomarker." "the best situation is where the target is so ubiquitous, like tisotumab vedotin, that you don't need it. [the biomarker]"
-
Aktier/tendens: Novozymes til eksamen med årstal før ventet grøn start
https://www.proinvestor.com/investornyt/774107/aktier-tendens-novozymes-til-eksamen-med-arstal-for-ventet-gron-start -
on 2021’s US Food and Drug Administration (FDA) drug approvals https://www.nature.com/articles/s41587-022-01208-2
-
and a bit more on that for those interested
https://www.fda.gov/media/155227/download -
Thanks E L.
-
Aktier/middag: Grøn dag - Novozymes i den røde ende efter tal
https://www.proinvestor.com/investornyt/774155/aktier-middag-gron-dag-novozymes-i-den-rode-ende-efter-tal -
Biogen Inc. (Nasdaq: BIIB) today announced that it exercised its option to participate in the development and commercialization of mosunetuzumab. Biogen will pay a $30 million one-time option fee to Genentech, a member of the Roche Group, as part of the companies’ long-standing collaboration on antibodies targeting CD20. https://investors.biogen.com/news-releases/news-release-details/biogen-exercises-option-participate-development-and
-
update of the EPCORE CLL-1 trial, adding 1 arm to focus on Richter's Syndrome https://clinicaltrials.gov/ct2/history/NCT04623541?A=3&B=4&C=merged#StudyPageTop https://www.cancerresearchuk.org/about-cancer/non-hodgkin-lymphoma/types/richters-syndrome
-
New spanish Maintenance trial with Bortezomib Plus Daratumumab (V-Dara) https://clinicaltrials.gov/ct2/show/NCT05218603
-
EL is the ØU analysis available now?
)Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind